SRC Antibody

What is SRC protein and why is it significant in research?

SRC (proto-oncogene tyrosine-protein kinase Src) is a ubiquitously-expressed cytoplasmic tyrosine kinase that regulates diverse cellular functions. Its historical significance stems from being the first oncogene identified, originally discovered as the cellular counterpart of v-Src found in the Rous sarcoma virus . SRC functions as a molecular switch, self-modulating its activity through a reciprocally regulatory mechanism involving Tyr416 and Tyr527, which changes the tertiary structure of SRC and controls access to its active site . The protein plays crucial roles in signal transduction pathways related to cell proliferation, differentiation, migration, and survival, making it a central focus in cancer research, developmental biology, and immunology studies.

How do I select the appropriate SRC antibody for my research application?

Selection of an appropriate SRC antibody depends on several experimental factors: (1) Target species compatibility - confirm reactivity with your species of interest (human, mouse, rat) ; (2) Application specificity - different antibodies perform optimally in specific applications such as Western blot, immunohistochemistry, or flow cytometry ; (3) Epitope recognition - some antibodies target total SRC while others recognize phosphorylated forms at specific residues like Y419 ; (4) Clonality - monoclonal antibodies offer high specificity but limited epitope recognition, while polyclonal antibodies provide broader detection but potential cross-reactivity; (5) Validation status - prioritize antibodies with demonstrated specificity in publications or manufacturer validation data showing detection at the expected molecular weight (~60 kDa for SRC) . Review experimental validation data provided by manufacturers to ensure the antibody performs reliably in your specific application.

What are the typical expression patterns of SRC in different tissues and cell lines?

SRC expression varies across tissues and cell types, with consistent detection patterns revealed through antibody-based studies. In human tissues, SRC is detectable in liver, colon, and various cancer tissues using antibodies such as AF3389 . At the cellular level, SRC is consistently detected in numerous cell lines including: MCF-7 (human breast cancer), Y3-Ag (rat myeloid), Rat-2 (rat embryonic fibroblast), A549 (human lung carcinoma), HepG2 (human hepatocellular carcinoma), and MDA-MB-468 (human breast cancer) . Notably, certain cell lines consistently show negative or minimal SRC expression, including U937 (human histiocytic lymphoma) and HL-60 (human acute promyelocytic leukemia) . These expression patterns provide valuable benchmarks for researchers designing experiments, selecting positive and negative controls, and validating antibody performance.

How do I optimize Western blot protocols for detecting SRC with antibodies?

Optimizing Western blot protocols for SRC detection requires attention to several key factors. Based on validated protocols, prepare lysates using appropriate lysis buffers containing protease inhibitors to prevent degradation and phosphatase inhibitors when detecting phosphorylated forms . Use reducing conditions with SDS-PAGE separation, as most SRC antibodies are validated under these conditions . Load appropriate amounts of protein (typical ranges from studies show 0.2-1 mg/mL concentration) . When probing membranes, optimal antibody concentrations range from 0.5-1 μg/mL for many commercial antibodies . For detection, both HRP-conjugated secondary antibodies are commonly used with successful detection . Expected molecular weight for SRC is approximately 60 kDa, though some detection methods may show it at 62 kDa . Include appropriate loading controls (GAPDH is commonly used) . For enhanced detection of phosphorylated SRC forms, additional membrane blocking strategies may be necessary to reduce background and increase specificity .

What are the considerations for immunohistochemical detection of SRC in tissue samples?

Successful immunohistochemical detection of SRC requires careful protocol optimization. Based on validated methods, use paraffin-embedded tissue sections with appropriate antigen retrieval methods . Fixation techniques significantly impact antibody accessibility to SRC epitopes - most successful protocols use immersion-fixed paraffin-embedded sections . For optimal staining, antibody concentrations between 10-15 μg/mL have proven effective when incubated overnight at 4°C . Detection systems such as HRP-DAB (horseradish peroxidase-diaminobenzidine) provide good visualization of SRC localization, with counterstaining using hematoxylin to provide cellular context . When detecting phosphorylated forms of SRC, additional blocking steps may be necessary to prevent non-specific binding . Validation should include both positive controls (tissues known to express SRC, such as colon and liver) and negative controls (omitting primary antibody) . Multiple publications have successfully demonstrated SRC detection in human liver, colon, and cancer tissues using these approaches .

How can I effectively use SRC antibodies in multiplexed immunofluorescence studies?

Multiplexed immunofluorescence studies with SRC antibodies require careful antibody panel design to avoid spectral overlap and cross-reactivity. Based on published protocols, successful co-staining has been achieved with markers like F4/80 (macrophage marker) alongside either total SRC or phosphorylated SRC antibodies . When designing multiplexed panels, primary antibody species compatibility is critical - select antibodies raised in different host species to avoid cross-reactivity with secondary antibodies . Sequential staining protocols have proven effective, with overnight incubation of the first primary antibody (e.g., anti-SRC) followed by shorter incubation periods (approximately 1 hour) for subsequent antibodies . For optimal resolution of subcellular SRC localization, confocal microscopy provides superior results compared to conventional fluorescence microscopy. Careful titration of each antibody is essential when introducing multiple markers to minimize background and spillover. Successful multiplexed studies have employed techniques such as tyramide signal amplification to enhance detection sensitivity while maintaining specificity .

How do I distinguish between SRC and other SRC family kinases using antibodies?

Distinguishing between SRC and other SRC family kinases (SFKs) presents a significant challenge due to high sequence homology. To achieve specific detection, employ antibodies that target unique regions of SRC not conserved among other family members. Manufacturer validation data should explicitly state cross-reactivity profiles against other SFKs such as Fyn, Yes, and Lck . For confirmatory experiments, utilize multiple antibodies targeting different epitopes of SRC, as convergent results increase confidence in specificity. Consider implementing knockdown/knockout validation approaches in your study design - cells with SRC specifically depleted should show reduced or absent signal compared to controls . Phospho-specific antibodies targeting SRC activation sites (e.g., Y419) may exhibit cross-reactivity with homologous phosphorylation sites on other SFKs, as indicated by comparable immunoreactivity patterns between phosphorylated SRC family antibodies and general phosphotyrosine antibodies . Complementary techniques such as mass spectrometry can provide definitive identification when antibody-based discrimination is challenging.

What strategies should I use to validate phospho-SRC antibody specificity in my experimental system?

Validating phospho-SRC antibody specificity requires a multi-faceted approach. First, implement pharmacological validation by treating cells with SRC-specific inhibitors (such as PP2, dasatinib, or saracatinib) - this should result in decreased phospho-SRC signal while total SRC remains unchanged . Second, employ genetic validation through SRC knockdown or knockout models, which should show reduced or absent phospho-SRC signal. Third, utilize phosphatase treatment controls - treating lysates with phosphatases prior to analysis should eliminate phospho-SRC signal while preserving total SRC detection . Fourth, compare reactivity patterns between phospho-SRC-specific antibodies and general phosphotyrosine antibodies (such as 4G10 clone) to confirm consistent detection patterns . Finally, establish signal specificity through peptide competition assays using phosphorylated and non-phosphorylated peptides corresponding to the antibody epitope region. For Western blot applications, detection of a single band at the expected molecular weight (~60 kDa) provides additional confirmation of specificity .

How can I quantitatively assess SRC activation dynamics in live cells using antibody-based approaches?

Quantitative assessment of SRC activation dynamics in live cells requires specialized antibody-based techniques that preserve cellular integrity. Phospho-specific antibody fragments (Fabs) conjugated to fluorophores can be introduced into cells through microinjection or cell-penetrating peptide conjugation approaches. For dynamic measurements, fluorescence resonance energy transfer (FRET)-based biosensors incorporating SRC-specific antibody fragments provide real-time visualization of SRC conformational changes associated with activation. Alternatively, implement proximity ligation assays (PLA) using antibodies targeting both total SRC and phosphorylated SRC to generate quantifiable fluorescent signals when both epitopes are in close proximity. Time-lapse microscopy combined with these approaches enables tracking of spatial and temporal SRC activation patterns following stimulation. For highest sensitivity in detecting subtle changes in activation state, consider combining antibody-based methods with genetically encoded reporters of SRC activity, validating findings through complementary approaches.

Why might I observe multiple bands in Western blots using SRC antibodies?

Multiple bands in SRC Western blots can result from several biological and technical factors requiring systematic troubleshooting. First, check if the additional bands represent physiological SRC isoforms - while the canonical SRC migrates at approximately 60 kDa, alternative splicing variants may produce additional bands . Second, post-translational modifications like phosphorylation can cause mobility shifts - particularly notable when using general SRC antibodies that recognize both phosphorylated and non-phosphorylated forms . Third, proteolytic degradation during sample preparation may generate SRC fragments - ensure protease inhibitors are included in lysis buffers and samples are kept cold . Fourth, cross-reactivity with other SRC family kinases (Fyn, Yes, Lck) is common due to high sequence homology . Fifth, non-specific binding due to insufficient blocking or excessive antibody concentration can produce spurious bands - titrate antibody concentrations (successful studies used 0.5-1 μg/mL) and optimize blocking conditions . Finally, antibody quality issues may occur - compare results using antibodies from alternative sources or different clones targeting distinct SRC epitopes to confirm band specificity.

What controls should I include when detecting phosphorylated SRC in my experiments?

Robust experimental design for phosphorylated SRC detection requires multiple control strategies. Include positive controls consisting of lysates from cell lines with known constitutive SRC activation, such as certain cancer cell lines (HepG2, MDA-MB-468) or cells stimulated with growth factors that activate SRC. Incorporate negative controls including cell lines with minimal SRC expression (U937, HL-60) or cells treated with SRC kinase inhibitors to abolish phosphorylation. For Western blotting, include parallel blots for total SRC detection to normalize phospho-SRC signals and confirm equal loading with housekeeping proteins like GAPDH . Implement technical controls including phosphatase-treated samples to confirm signal specificity for phosphorylated epitopes . For immunocytochemistry or immunohistochemistry applications, include antibody specificity controls (primary antibody omission), isotype controls, and phosphatase-treated sections . When analyzing results, present phospho-SRC data normalized to total SRC levels rather than as standalone measurements to accurately reflect activation state changes independent of expression level variations.

How do I address inconsistent results between different lots of the same SRC antibody?

Addressing inconsistencies between antibody lots requires systematic validation and standardization approaches. First, implement side-by-side testing of new and previous antibody lots on identical samples under identical conditions to directly assess performance differences. Second, maintain a reference sample set (positive and negative controls) that can be used to qualify each new antibody lot before use in critical experiments . Third, consider bridging studies where both lots are used in parallel on a subset of experimental samples to establish conversion factors if necessary. Fourth, create detailed documentation of antibody performance characteristics including optimal dilutions, incubation conditions, and expected signal patterns for each lot . Fifth, communicate with manufacturers about observed inconsistencies, as they may provide validation data specific to the lots in question or replacement products if quality issues are confirmed. Finally, if possible, purchase sufficient quantities of a single lot for critical long-term studies to eliminate lot-to-lot variability entirely.

How should I interpret discrepancies between total SRC and phospho-SRC antibody results?

Discrepancies between total SRC and phospho-SRC antibody results require careful interpretation considering both biological and technical factors. Biologically, these differences may reflect genuine regulatory mechanisms - SRC activation (phosphorylation at Y419) can occur independently of changes in total SRC expression, representing increased specific activity rather than protein abundance . Conversely, altered total SRC without corresponding phospho-SRC changes may indicate inactive protein accumulation. Technically, epitope accessibility differences between total and phospho-specific antibodies can affect detection efficiency - phosphorylation can induce conformational changes that mask or expose epitopes targeted by total SRC antibodies . Sensitivity differences between antibodies may also occur - phospho-specific antibodies often detect smaller subpopulations of the total protein pool. To resolve these discrepancies, complement antibody-based methods with functional assays measuring SRC kinase activity directly. Additionally, use multiple antibodies targeting different epitopes of both total and phosphorylated SRC, and verify findings with orthogonal techniques such as mass spectrometry to distinguish between technical artifacts and genuine biological phenomena .

What experimental design considerations are critical when studying SRC in cancer models using antibodies?

Studying SRC in cancer models requires careful experimental design considering several factors specific to oncogenic contexts. First, select appropriate model systems based on known SRC expression patterns - validated positive models include A549 (lung carcinoma), HepG2 (hepatocellular carcinoma), MCF-7 and MDA-MB-468 (breast cancer), while U937 and HL-60 serve as negative controls . Second, incorporate heterogeneity assessment by analyzing multiple regions within tumor samples or multiple clones from cell lines, as SRC expression and activation can vary within a single tumor . Third, implement context-specific controls - compare tumor samples with adjacent normal tissue or isogenic cell lines with different malignant potential. Fourth, consider microenvironmental factors that influence SRC activity - co-culture systems or conditioned media approaches may better recapitulate in vivo SRC regulation . Fifth, assess both expression and activation status using total and phospho-specific antibodies respectively, as oncogenic effects often involve altered activation rather than mere overexpression . Finally, complement antibody-based detection with functional readouts of SRC-dependent phenotypes, such as migration, invasion, or proliferation assays with SRC inhibitors as validation controls.

How can I effectively combine SRC antibodies with other research tools to gain comprehensive insights into SRC signaling pathways?

Comprehensive investigation of SRC signaling requires integrating antibody-based approaches with complementary methodologies. First, combine immunoprecipitation using SRC antibodies with mass spectrometry to identify novel interaction partners and post-translational modifications beyond phosphorylation . Second, implement proximity labeling techniques (BioID, APEX) with SRC-specific antibody validation to map dynamic interaction networks in living cells. Third, integrate SRC antibody-based imaging with functional assays that measure downstream pathway activation, such as reporter gene assays or phosphorylation status of known SRC substrates. Fourth, employ genetic approaches (CRISPR-Cas9, RNAi) targeting SRC alongside antibody detection of pathway components to establish causal relationships and validate antibody specificity simultaneously . Fifth, utilize pharmacological tools (kinase inhibitors with varying specificity profiles) in combination with phospho-specific antibodies to delineate SRC-dependent and independent signaling events. Finally, incorporate computational modeling approaches that integrate antibody-derived quantitative data on SRC expression and activation with pathway analysis to predict system-level responses to perturbations. This multi-modal approach provides validation through methodological convergence while revealing aspects of SRC biology inaccessible to antibody-based methods alone.

What emerging technologies are enhancing the capabilities of SRC antibody applications in research?

Emerging technologies are significantly expanding the utility of SRC antibodies in research applications. Single-cell antibody-based methods, including mass cytometry (CyTOF) and single-cell Western blotting, now enable analysis of SRC expression and phosphorylation states at unprecedented resolution, revealing heterogeneity masked in bulk population analyses. Super-resolution microscopy techniques, when combined with highly specific SRC antibodies, permit visualization of nanoscale spatial organization of SRC signaling complexes previously undetectable with conventional microscopy . Antibody engineering approaches have yielded recombinant SRC antibody fragments with enhanced tissue penetration and reduced background for improved in vivo imaging. Proximity-dependent techniques including proximity ligation assays are being refined to detect specific SRC protein interactions at endogenous expression levels. Additionally, validation technologies using gene editing to introduce epitope tags into endogenous SRC are providing definitive benchmarks for antibody specificity assessment. As these technologies mature, researchers will gain increasingly nuanced insights into SRC biology while maintaining the specificity advantages of antibody-based detection.